Abstract
A t(2;5) (p23;q35) chromosomal translocation can be found in a high percentage of anaplastic large-cell lymphomas (ALCL). This genetic abnormality leads to the expression of the NPM–ALK fusion protein, which encodes a constitutively active tyrosine kinase that plays a causative role in lymphomagenesis. Employing a modified infection/transplantation protocol utilizing an MSCV-based vector, we were able to reproducibly induce two phenotypically different lymphoma-like diseases dependent on the retroviral titers used. The first phenotype presented as a polyclonal histiocytic malignancy of myeloid/macrophage origin with a short latency period of 3–4 weeks. Clinically, the diseased mice showed rapidly progressive wasting, lymphadenopathy and pancytopenia. Mice displaying the second phenotype developed monoclonal B-lymphoid tumors with a longer latency of approximately 12–16 weeks, primarily involving the spleen and the bone marrow, with less extensive lymph node but also histologically evident extranodal organ infiltration by large immature plasmoblastic cells. The described retroviral mouse model will be useful to analyse the role of NPM–ALK in lymphomagenesis in vivo and may contribute to the development of new treatment options for NPM–ALK induced malignancies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bai RY, Dieter P, Peschel C, Morris SW and Duyster J . (1998). Mol. Cell. Biol., 18, 6951–6961.
Bai RY, Ouyang T, Miething C, Morris SW, Peschel C and Duyster J . (2000). Blood, 96, 4319–4327.
Beecham EJ, Mushinski JF, Shacter E, Potter M and Bohr VA . (1991). Mol. Cell. Biol, 11, 3095–3104.
Bischof D, Pulford K, Mason DY and Morris SW . (1997). Mol. Cell. Biol., 17, 2312–2325.
Cheuk W, Hill RW, Bacchi C, Dias MA and Chan JK . (2000). Am. J. Surg. Pathol., 24, 1537–1543.
Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS, Van Aelst L and Pandolfi PP . (2001). J. Exp. Med., 194, 275–284.
Drexler HG, Gignac SM, von Wasielewski R, Werner M and Dirks WG . (2000). Leukemia, 14, 1533–1559.
Duyster J, Bai RY and Morris SW . (2001). Oncogene, 20, 5623–5637.
Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG and Flenghi L . (1998). Am. J. Pathol., 153, 875–886.
Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF and Santucci A . (1999). Blood, 93, 2697–2706.
Hawley RG, Lieu FH, Fong AZ and Hawley TS . (1994). Gene Therapy, 1, 136–138.
Hideshima T, Nakamura N, Chauhan D and Anderson KC . (2001). Oncogene, 20, 5991–6000.
Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS and Li W . (2000). Blood, 96, 3560–3568.
Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY and Morris SW . (1997). Blood, 90, 2901–2910.
Largaespada DA, Kaehler DA, Mishak H, Weissinger E, Potter M, Mushinski JF and Risser R . (1992). Oncogene, 7, 811–819.
Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG and Van Etten RA . (2001). Blood, 97, 1442–1450.
Li S, Ilaria Jr RL, Million RP, Daley GQ and Van Etten RA . (1999). J. Exp. Med., 189, 1399–1412.
Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G and Morris SW . (1998). Cancer. Res., 58, 1057–1062.
Million RP and Van Etten RA . (2000). Blood, 96, 664–670.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL and Look AT . (1994). Science, 263, 1281–1284.
Morris SW, Xue L, Ma Z and Kinney MC . (2001). Br. J. Haematol., 113, 275–295.
Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW and Skorski T . (2001). Cancer. Res., 61, 6517–6523.
Parker JR, Lopez-Terrada D, Gresik MV, Vogel H, Baumgartner JE and Finegold MJ . (2001). Pediatr. Dev. Pathol., 4, 397–401.
Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML and Baltimore D . (1998). Blood, 92, 3780–3792.
Pear WS, Nolan GP, Scott ML and Baltimore D . (1993). Proc. Natl. Acad. Sci. USA, 90, 8392–8396.
Potter M, Wax J, Mushinski E, Brust S, Babonits M, Wiener F, Mushinski JF, Mezebish D, Skurla R and Rapp U . (1986). Curr. Top Microbiol. Immunol., 132, 40–43.
Potter M, Wax JS, Hansen CT and Kenny JJ . (1999). Int. Immunol., 11, 1059–1064.
Rawat R, Rainey GJ, Thompson CD, Frazier-Jessen MR, Brown RT and Nordan RP . (2000). Blood, 96, 3514–3521.
Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL and Van Etten RA . (2001). Blood, 97, 4–13.
Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, Rothammer K, Roussel MF and Ihle JN . (2000). Blood, 96, 2277–2283.
Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA and Skorski T . (2001). Cancer Res., 61, 2194–2199.
Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S and Falini B . (2000). Blood, 96, 3681–3695.
Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G and Lemke H . et al. (1985). Blood, 66, 848–858.
Troppmair J, Potter M, Wax JS and Rapp UR . (1989). Proc. Natl. Acad. Sci. USA, 86, 9941–9945.
Tu Y, Gardner A and Lichtenstein A . (2000). Cancer Res., 60, 6763–6770.
Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T and Wasik MA . (2002). J. Immunol., 168, 466–474.
Zhang X and Ren R . (1998). Blood, 92, 3829–3840.
Zhang X, Subrahmanyam R, Wong R, Gross AW and Ren R . (2001). Mol. Cell. Biol., 21, 840–853.
Acknowledgements
JD is supported by a grant from the Wilhelm-Sander Stiftung. CM is supported by a fellowship from the Deutsche Jose Carreras Leukämie Stiftung (DJCLS 2001/NAT-2). The work was also supported by National Cancer Institute (NCI) Grant CA69129 (SWM), NCI Cancer Center Core Grant CA21765 and by the American Lebanese Syrian Associated Charities (ALSAC), St Jude Children's Research Hospital. We thank W Pear for supplying the MigRI retroviral vector.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miething, C., Grundler, R., Fend, F. et al. The oncogenic fusion protein nucleophosmin–anaplastic lymphoma kinase (NPM–ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 22, 4642–4647 (2003). https://doi.org/10.1038/sj.onc.1206575
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206575
Keywords
This article is cited by
-
A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette
Oncogene (2020)
-
Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3+-mediated leukemic phenotype
Leukemia (2016)
-
Molecular Pathogenesis of Peripheral T Cell Lymphoma
Current Hematologic Malignancy Reports (2015)
-
T-cell receptor diversity prevents T-cell lymphoma development
Leukemia (2012)
-
Rab35
AfCS-Nature Molecule Pages (2008)